HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
How PROTACs differ from SERDs/CERDs
Hamilton explains hetero‑bifunctional PROTAC action, E3 ligase recruitment and potential advantages in resistance.
Play episode from 03:19
Transcript
